LXRX – Lexicon Pharmaceuticals Inc.
LXRX — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
11.39
Margin Of Safety %
Put/Call OI Ratio
0.03
EPS Next Q Diff
EPS Last/This Y
-0.02
EPS This/Next Y
-0.05
Price
2.16
Target Price
3.72
Analyst Recom
1.8
Performance Q
43.05
Upside
-142.1%
Beta
1.03
Ticker: LXRX
21 items
«
‹
of 1
›
»
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-04-24 | LXRX | 1.675 | 0.03 | 0.01 | 31631 |
| 2026-04-27 | LXRX | 1.695 | 0.03 | 0.03 | 31997 |
| 2026-04-28 | LXRX | 1.665 | 0.03 | 0.00 | 32301 |
| 2026-04-29 | LXRX | 1.555 | 0.03 | 0.05 | 32624 |
| 2026-04-30 | LXRX | 1.62 | 0.03 | 0.00 | 32730 |
| 2026-05-01 | LXRX | 1.635 | 0.03 | 0.23 | 33008 |
| 2026-05-04 | LXRX | 1.595 | 0.03 | 0.02 | 33082 |
| 2026-05-05 | LXRX | 1.645 | 0.03 | 0.17 | 33105 |
| 2026-05-06 | LXRX | 1.615 | 0.03 | 0.00 | 33178 |
| 2026-05-07 | LXRX | 1.685 | 0.03 | 0.04 | 33147 |
| 2026-05-08 | LXRX | 2 | 0.03 | 0.03 | 33212 |
| 2026-05-11 | LXRX | 2.3 | 0.03 | 0.01 | 33662 |
| 2026-05-12 | LXRX | 2.4 | 0.03 | 0.06 | 35284 |
| 2026-05-13 | LXRX | 2.44 | 0.03 | 0.00 | 35338 |
| 2026-05-14 | LXRX | 2.33 | 0.03 | 0.01 | 35783 |
| 2026-05-15 | LXRX | 2.22 | 0.03 | 0.01 | 35868 |
| 2026-05-18 | LXRX | 2.14 | 0.03 | 0.06 | 30690 |
| 2026-05-19 | LXRX | 2.12 | 0.03 | 0.03 | 30925 |
| 2026-05-20 | LXRX | 2.22 | 0.03 | 0.10 | 31116 |
| 2026-05-21 | LXRX | 2.22 | 0.03 | 0.44 | 31197 |
| 2026-05-22 | LXRX | 2.16 | 0.03 | 0.00 | 31328 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
21 items
«
‹
Current Page1 of 1
›
»
21 items
«
‹
of 1
›
»
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-04-24 | LXRX | 1.67 | 50.0 | -29.5 | -0.18 |
| 2026-04-27 | LXRX | 1.69 | 50.0 | -30.2 | -0.18 |
| 2026-04-28 | LXRX | 1.66 | 50.0 | -28.7 | -0.18 |
| 2026-04-29 | LXRX | 1.55 | 50.0 | -25.0 | -0.18 |
| 2026-04-30 | LXRX | 1.62 | 50.0 | -33.2 | -0.18 |
| 2026-05-01 | LXRX | 1.63 | 50.0 | -30.5 | -0.18 |
| 2026-05-04 | LXRX | 1.60 | 50.0 | -28.1 | -0.18 |
| 2026-05-05 | LXRX | 1.65 | 50.0 | -32.4 | -0.18 |
| 2026-05-06 | LXRX | 1.62 | 50.0 | -28.2 | -0.18 |
| 2026-05-07 | LXRX | 1.68 | 50.0 | -32.8 | -0.18 |
| 2026-05-08 | LXRX | 2.00 | 50.0 | -44.1 | -0.18 |
| 2026-05-11 | LXRX | 2.30 | 50.0 | -66.2 | -0.18 |
| 2026-05-12 | LXRX | 2.41 | -650.0 | -57.9 | -0.18 |
| 2026-05-13 | LXRX | 2.44 | -650.0 | -46.0 | -0.18 |
| 2026-05-14 | LXRX | 2.33 | -650.0 | -41.6 | -0.18 |
| 2026-05-15 | LXRX | 2.23 | -650.0 | -41.9 | -0.16 |
| 2026-05-18 | LXRX | 2.14 | -602.3 | -42.1 | -0.16 |
| 2026-05-19 | LXRX | 2.12 | -602.3 | -44.2 | -0.16 |
| 2026-05-20 | LXRX | 2.21 | -602.3 | -47.5 | -0.16 |
| 2026-05-21 | LXRX | 2.22 | -602.3 | -45.3 | -0.16 |
| 2026-05-22 | LXRX | 2.16 | -602.3 | -42.9 | -0.16 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
21 items
«
‹
Current Page1 of 1
›
»
21 items
«
‹
of 1
›
»
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-04-24 | LXRX | 1.02 | -29.69 | 10.41 |
| 2026-04-27 | LXRX | 1.02 | -29.67 | 10.75 |
| 2026-04-28 | LXRX | 1.02 | -29.67 | 10.75 |
| 2026-04-29 | LXRX | 1.02 | -29.67 | 10.75 |
| 2026-04-30 | LXRX | 1.02 | -29.67 | 10.75 |
| 2026-05-01 | LXRX | 1.02 | -29.67 | 10.75 |
| 2026-05-04 | LXRX | 1.02 | -28.81 | 10.75 |
| 2026-05-05 | LXRX | 1.02 | -28.81 | 10.75 |
| 2026-05-06 | LXRX | 1.02 | -28.81 | 10.75 |
| 2026-05-07 | LXRX | 1.02 | -28.81 | 10.75 |
| 2026-05-08 | LXRX | 1.02 | -28.81 | 10.75 |
| 2026-05-11 | LXRX | 0.97 | -28.80 | 10.25 |
| 2026-05-12 | LXRX | 0.97 | -28.80 | 10.33 |
| 2026-05-13 | LXRX | 0.97 | -28.80 | 10.33 |
| 2026-05-14 | LXRX | 0.97 | -28.80 | 10.33 |
| 2026-05-15 | LXRX | 0.97 | -28.80 | 10.33 |
| 2026-05-18 | LXRX | 0.97 | 1.78 | 11.39 |
| 2026-05-19 | LXRX | 0.89 | 1.78 | 11.39 |
| 2026-05-20 | LXRX | 0.89 | 1.78 | 11.39 |
| 2026-05-21 | LXRX | 0.89 | 1.78 | 11.39 |
| 2026-05-22 | LXRX | 0.89 | 1.78 | 11.39 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
21 items
«
‹
Current Page1 of 1
›
»
Last Quarter Act. EPS
Avg. EPS Est. Current Quarter
-0.05
Avg. EPS Est. Next Quarter
-0.06
Insider Transactions
0.89
Institutional Transactions
1.78
Beta
1.03
Average Sales Estimate Current Quarter
3
Average Sales Estimate Next Quarter
3
Fair Value
Quality Score
53
Growth Score
36
Sentiment Score
82
Actual DrawDown %
65.9
Max Drawdown 5-Year %
-95.2
Target Price
3.72
P/E
Forward P/E
PEG
P/S
13.78
P/B
4.51
P/Free Cash Flow
EPS
-0.07
Average EPS Est. Cur. Y
-0.16
EPS Next Y. (Est.)
-0.21
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-37.46
Relative Volume
0.61
Return on Equity vs Sector %
-39.9
Return on Equity vs Industry %
-24.3
EPS 1 7Days Diff
EPS 1 30Days Diff
0.02
EBIT Estimation
-42.9
◆
LXRX
Healthcare
$2.16
📉
Swing / Pullback
Buy the dip on strong trends
WEAK
Trend
0/20
Pullback
10/25
Volume
9/15
Valuation
9/20
TP/AR
3/10
Options
8/10
RSI
59.2
Range 1M
63.9%
Sup Dist
0.9%
🚀
N/A
Momentum Growth
Ride accelerating trends
WEAK
Momentum
5/25
Growth
10/30
Estimates
3/20
Inst/Vol
7/15
Options
6/10
EPS Yr
-13.3%
EPS NY
-30%
52W%
80.9%
💎
N/A
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+72.2% upside
Quality
6/30
Valuation
13/30
Growth
6/25
Stability
6/10
LT Trend
1/5
Upside
+72.2%
Quality
53
Click a card to see score breakdown
Full Analysis →
Sector: Healthcare
Industry: Biotechnology
Employees: 81
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, CKD, and other cardiovascular risk factors. In addition, the company develops LX9851, an orally-delivered small molecule drug candidate for the treatment of obesity and associated cardiometabolic disorders, and pilavapadin (LX9211), an orally-delivered small molecule drug candidate for the treatment of neuropathic pain. It has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
LXRX
Latest News
—
Caricamento notizie per LXRX…
stock quote shares LXRX – Lexicon Pharmaceuticals Inc. Stock Price stock today
news today LXRX – Lexicon Pharmaceuticals Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch LXRX – Lexicon Pharmaceuticals Inc. yahoo finance google finance
stock history LXRX – Lexicon Pharmaceuticals Inc. invest stock market
stock prices LXRX premarket after hours
ticker LXRX fair value insiders trading